首页 > 最新文献

European Heart Journal - Quality of Care and Clinical Outcomes最新文献

英文 中文
Ambulance drive-thru troponin, ready to go? 救护车车载肌钙蛋白,准备好了吗?
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae023
Héctor Bueno, Alfredo Bardají
{"title":"Ambulance drive-thru troponin, ready to go?","authors":"Héctor Bueno, Alfredo Bardají","doi":"10.1093/ehjqcco/qcae023","DOIUrl":"10.1093/ehjqcco/qcae023","url":null,"abstract":"","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global, regional, and national burden of atrial fibrillation/flutter related to metabolic risks over three decades: estimates from the global burden of disease study 2019. 三十年来与代谢风险相关的全球、地区和国家心房颤动/扑动负担:2019 年全球疾病负担研究的估计值。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae033
Xi Jiang, Jianen Ling, Qingsong Xiong, Weijie Chen, Lili Zou, Zhiyu Ling

Aims: Atrial fibrillation/atrial flutter (AF/AFL) remains a significant public health concern on a global scale, with metabolic risks playing an increasingly prominent role. This study aimed to investigate comprehensive epidemiological data and trends concerning the metabolic risks related-AF/AFL burden based on the data from the Global Burden of Disease study in 2019.

Methods and results: The analysis of disease burden focused on numbers, age-standardized rates of deaths, disability-adjusted life years (DALYs), and estimated annual percentage change, while considering factors of age, sex, sociodemographic index (SDI), and locations. In 2019, there was a culmination of 137 179 deaths and 4 099 146 DALYs caused by metabolic risks related-AF/AFL worldwide, with an increase of 162.95% and 120.30%, respectively from 1990. High and high-middle SDI regions predominantly carried the burden of AF/AFL associated with metabolic risks, while a shift towards lower SDI regions had been occurring. Montenegro had the highest recorded death rate (7.6 per 100 000) and DALYs rate (146.3 per 100 000). An asymmetrically inverted V-shaped correlation was found between SDI and deaths/DALYs rates. Moreover, females and the elderly exhibited higher AF/AFL burdens, and young adults (over 40 years old) also experienced an annual increase.

Conclusion: The global AF/AFL burden related to metabolic risks has significantly increased over the past three decades, with considerable spatiotemporal, gender-based, and age-related heterogeneity. These findings shed valuable light on the trends in the burden of metabolic risks related-AF/AFL and offered insights into corresponding strategies.

目的:心房颤动/心房扑动(AF/AFL)仍然是全球范围内的重大公共卫生问题,其中代谢风险的作用日益突出。本研究旨在根据 2019 年全球疾病负担(GBD)研究的数据,调查与代谢风险相关的房颤/房扑负担的综合流行病学数据和趋势:疾病负担分析的重点是死亡人数、年龄标准化死亡率(ASR)、残疾调整生命年(DALYs)和估计年度百分比变化(EAPC),同时考虑年龄、性别、社会人口指数(SDI)和地点等因素。2019 年,全球因与代谢风险相关的 AF/AFL 导致的死亡人数为 137 179 人,DALYs 为 4 099 146 人,与 1990 年相比分别增长了 162.95% 和 120.30%。与代谢风险相关的心房颤动/心力衰竭的负担主要由高、中SDI地区承担,而向低SDI地区转移的趋势正在发生。黑山的死亡率(每 100 000 人中有 7.6 人)和残疾调整寿命年数(每 100 000 人中有 146.3 人)都是最高的。在 SDI 和死亡率/残疾调整寿命年数之间发现了不对称的倒 V 型相关关系。此外,女性和老年人的心房颤动/心力衰竭负担较重,年轻成年人(40 岁以上)的心房颤动/心力衰竭负担也在逐年增加:结论:过去三十年来,与代谢风险相关的全球心房颤动/心力衰竭负担显著增加,并具有相当大的时空、性别和年龄异质性。这些发现揭示了与代谢风险相关的心房颤动/心力衰竭负担的趋势,并为相应的策略提供了启示。
{"title":"Global, regional, and national burden of atrial fibrillation/flutter related to metabolic risks over three decades: estimates from the global burden of disease study 2019.","authors":"Xi Jiang, Jianen Ling, Qingsong Xiong, Weijie Chen, Lili Zou, Zhiyu Ling","doi":"10.1093/ehjqcco/qcae033","DOIUrl":"10.1093/ehjqcco/qcae033","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation/atrial flutter (AF/AFL) remains a significant public health concern on a global scale, with metabolic risks playing an increasingly prominent role. This study aimed to investigate comprehensive epidemiological data and trends concerning the metabolic risks related-AF/AFL burden based on the data from the Global Burden of Disease study in 2019.</p><p><strong>Methods and results: </strong>The analysis of disease burden focused on numbers, age-standardized rates of deaths, disability-adjusted life years (DALYs), and estimated annual percentage change, while considering factors of age, sex, sociodemographic index (SDI), and locations. In 2019, there was a culmination of 137 179 deaths and 4 099 146 DALYs caused by metabolic risks related-AF/AFL worldwide, with an increase of 162.95% and 120.30%, respectively from 1990. High and high-middle SDI regions predominantly carried the burden of AF/AFL associated with metabolic risks, while a shift towards lower SDI regions had been occurring. Montenegro had the highest recorded death rate (7.6 per 100 000) and DALYs rate (146.3 per 100 000). An asymmetrically inverted V-shaped correlation was found between SDI and deaths/DALYs rates. Moreover, females and the elderly exhibited higher AF/AFL burdens, and young adults (over 40 years old) also experienced an annual increase.</p><p><strong>Conclusion: </strong>The global AF/AFL burden related to metabolic risks has significantly increased over the past three decades, with considerable spatiotemporal, gender-based, and age-related heterogeneity. These findings shed valuable light on the trends in the burden of metabolic risks related-AF/AFL and offered insights into corresponding strategies.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140850880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cohort profile: the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)-acute coronary syndrome and percutaneous coronary intervention. 队列简介:欧洲心脏护理评估和随机试验统一登记处(EuroHeart)--急性冠状动脉综合症和经皮冠状动脉介入治疗。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae025
Asad Bhatty, Chris Wilkinson, Gorav Batra, Joakim Alfredsson, David Erlinge, Jorge Ferreira, Ingibjörg J Guðmundsdóttir, Þórdís Jóna Hrafnkelsdóttir, Inga Jóna Ingimarsdóttir, Alar Irs, Zoltán Járai, András Jánosi, Bogdan A Popescu, Manuel Santos, Peter Vasko, Dragos Vinereanu, Jonathan Yap, Aldo P Maggioni, Lars Wallentin, Barabara Casadei, Chris P Gale

Aims: The European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart) aims to improve the quality of care and clinical outcomes for patients with cardiovascular disease. The collaboration of acute coronary syndrome/percutaneous coronary intervention (ACS/PCI) registries is operational in seven vanguard European Society of Cardiology member countries.

Methods and results: Adults admitted to hospitals with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) are included, and individual patient-level data collected and aligned according to the internationally agreed EuroHeart data standards for ACS/PCI. The registries provide up to 155 variables spanning patient demographics and clinical characteristics, in-hospital care, in-hospital outcomes, and discharge medications. After performing statistical analyses on patient data, participating countries transfer aggregated data to EuroHeart for international reporting. Between 1st January 2022 and 31st December 2022, 40 021 admissions (STEMI 46.7%, NSTEMI 53.3%) were recorded from 192 hospitals in the seven vanguard countries: Estonia, Hungary, Iceland, Portugal, Romania, Singapore, and Sweden. The mean age for the cohort was 67.9 (standard deviation 12.6) years, and it included 12 628 (31.6%) women.

Conclusion: The EuroHeart collaboration of ACS/PCI registries prospectively collects and analyses individual data for ACS and PCI at a national level, after which aggregated results are transferred to the EuroHeart Data Science Centre. The collaboration will expand to other countries and provide continuous insights into the provision of clinical care and outcomes for patients with ACS and undergoing PCI. It will serve as a unique international platform for quality improvement, observational research, and registry-based clinical trials.

目的:欧洲心脏护理评估和随机试验统一登记处(EuroHeart)旨在提高心血管疾病患者的护理质量和临床疗效。急性冠状动脉综合征/经皮冠状动脉介入治疗(ACS/PCI)登记处的合作在七个欧洲心脏病学会先锋成员国开展:急性冠状动脉综合征/经皮冠状动脉介入治疗(ACS/PCI)登记处纳入了ST段抬高型心肌梗死(STEMI)和非ST段抬高型心肌梗死(NSTEMI)的成人住院患者,并根据国际商定的欧洲心脏病学会(EuroHeart)ACS/PCI数据标准收集和统一了患者的个人数据。登记处提供多达 155 个变量,涵盖患者人口统计学和临床特征、院内护理、院内预后和出院用药。2022 年 1 月 1 日至 2022 年 12 月 31 日期间,七个先锋国家的 192 家医院记录了 40 021 例入院患者(STEMI 46.7%,NSTEMI 53.3%):这些医院来自爱沙尼亚、匈牙利、冰岛、葡萄牙、罗马尼亚、新加坡和瑞典的 192 家医院。队列的平均年龄为 67.9 岁(标准差为 12.6 岁),其中包括 12 628 名女性(31.6%):欧洲心脏联盟的 ACS/PCI 登记合作在国家层面上对 ACS 和 PCI 的个人数据进行前瞻性收集和分析,然后将汇总结果传输到欧洲心脏联盟数据科学中心。这项合作将扩展到其他国家,并为 ACS 和 PCI 患者的临床治疗和疗效提供持续的洞察力。它将成为一个独特的国际平台,用于质量改进、观察研究和以登记为基础的临床试验。
{"title":"Cohort profile: the European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart)-acute coronary syndrome and percutaneous coronary intervention.","authors":"Asad Bhatty, Chris Wilkinson, Gorav Batra, Joakim Alfredsson, David Erlinge, Jorge Ferreira, Ingibjörg J Guðmundsdóttir, Þórdís Jóna Hrafnkelsdóttir, Inga Jóna Ingimarsdóttir, Alar Irs, Zoltán Járai, András Jánosi, Bogdan A Popescu, Manuel Santos, Peter Vasko, Dragos Vinereanu, Jonathan Yap, Aldo P Maggioni, Lars Wallentin, Barabara Casadei, Chris P Gale","doi":"10.1093/ehjqcco/qcae025","DOIUrl":"10.1093/ehjqcco/qcae025","url":null,"abstract":"<p><strong>Aims: </strong>The European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart) aims to improve the quality of care and clinical outcomes for patients with cardiovascular disease. The collaboration of acute coronary syndrome/percutaneous coronary intervention (ACS/PCI) registries is operational in seven vanguard European Society of Cardiology member countries.</p><p><strong>Methods and results: </strong>Adults admitted to hospitals with ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) are included, and individual patient-level data collected and aligned according to the internationally agreed EuroHeart data standards for ACS/PCI. The registries provide up to 155 variables spanning patient demographics and clinical characteristics, in-hospital care, in-hospital outcomes, and discharge medications. After performing statistical analyses on patient data, participating countries transfer aggregated data to EuroHeart for international reporting. Between 1st January 2022 and 31st December 2022, 40 021 admissions (STEMI 46.7%, NSTEMI 53.3%) were recorded from 192 hospitals in the seven vanguard countries: Estonia, Hungary, Iceland, Portugal, Romania, Singapore, and Sweden. The mean age for the cohort was 67.9 (standard deviation 12.6) years, and it included 12 628 (31.6%) women.</p><p><strong>Conclusion: </strong>The EuroHeart collaboration of ACS/PCI registries prospectively collects and analyses individual data for ACS and PCI at a national level, after which aggregated results are transferred to the EuroHeart Data Science Centre. The collaboration will expand to other countries and provide continuous insights into the provision of clinical care and outcomes for patients with ACS and undergoing PCI. It will serve as a unique international platform for quality improvement, observational research, and registry-based clinical trials.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profiling heart failure with preserved or mildly reduced ejection fraction by cluster analysis. 通过聚类分析剖析射血分数保留或轻度降低的心力衰竭。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae067
Lourdes Vicent, Nicolás Rosillo, Jorge Vélez, Guillermo Moreno, Pablo Pérez, José Luis Bernal, Germán Seara, Rafael Salguero-Bodes, Fernando Arribas, Héctor Bueno

Background: Significant knowledge gaps remain regarding the heterogeneity of heart failure (HF) phenotypes, particularly among patients with preserved or mildly reduced left ventricular ejection fraction (HFp/mrEF). Our aim was to identify HF subtypes within the HFp/mrEF population.

Methods: K-prototypes clustering algorithm was used to identify different HF phenotypes in a cohort of 2 570 patients diagnosed with HFmrEF or HFpEF. This algorithm employs the k-means algorithm for quantitative variables and k-modes for qualitative variables.

Results: We identified three distinct phenotypic clusters: Cluster A (n = 850, 33.1%), characterized by a predominance of women with low comorbidity burden; Cluster B (n = 830, 32.3%), mainly women with diabetes mellitus and high comorbidity; and Cluster C (n = 890, 34.5%), primarily men with a history of active smoking and respiratory comorbidities. Significant differences were observed in baseline characteristics and one-year mortality rates across the clusters: 18% for Cluster A, 33% for Cluster B, and 26.4% for Cluster C (P < 0.001). Cluster B had the shortest median time to death (90 days), followed by Clusters C (99 days) and A (144 days) (P < 0.001). Stratified Cox regression analysis identified age, cancer, respiratory failure, and laboratory parameters as predictors of mortality.

Conclusion: Cluster analysis identified three distinct phenotypes within the HFp/mrEF population, highlighting significant heterogeneity in clinical profiles and prognostic implications. Women were classified into two distinct phenotypes: low-risk women and diabetic women with high mortality rates, while men had a more uniform profile with a higher prevalence of respiratory disease.

背景:关于心力衰竭(HF)表型的异质性,尤其是左心室射血分数保留或轻度降低(HFp/mrEF)患者的表型,仍存在很大的知识差距。我们的目的是在 HFp/mrEF 群体中识别 HF 亚型:方法:在2 570名被诊断为HFmrEF或HFpEF的患者中,采用K-原型聚类算法识别不同的HF表型。该算法对定量变量采用k-means算法,对定性变量采用k-modes算法:结果:我们发现了三个不同的表型集群:A群(n = 850,33.1%),以女性为主,合并症负担较低;B群(n = 830,32.3%),主要是患有糖尿病和高合并症的女性;C群(n = 890,34.5%),主要是有主动吸烟史和呼吸系统合并症的男性。各组群的基线特征和一年死亡率存在显著差异:群组 A 的死亡率为 18%,群组 B 为 33%,群组 C 为 26.4%(P,结论):聚类分析在 HFp/mrEF 人群中发现了三种不同的表型,突显了临床特征和预后影响方面的显著异质性。女性被分为两种不同的表型:低风险女性和高死亡率的糖尿病女性,而男性的表型较为一致,呼吸系统疾病的发病率较高。
{"title":"Profiling heart failure with preserved or mildly reduced ejection fraction by cluster analysis.","authors":"Lourdes Vicent, Nicolás Rosillo, Jorge Vélez, Guillermo Moreno, Pablo Pérez, José Luis Bernal, Germán Seara, Rafael Salguero-Bodes, Fernando Arribas, Héctor Bueno","doi":"10.1093/ehjqcco/qcae067","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae067","url":null,"abstract":"<p><strong>Background: </strong>Significant knowledge gaps remain regarding the heterogeneity of heart failure (HF) phenotypes, particularly among patients with preserved or mildly reduced left ventricular ejection fraction (HFp/mrEF). Our aim was to identify HF subtypes within the HFp/mrEF population.</p><p><strong>Methods: </strong>K-prototypes clustering algorithm was used to identify different HF phenotypes in a cohort of 2 570 patients diagnosed with HFmrEF or HFpEF. This algorithm employs the k-means algorithm for quantitative variables and k-modes for qualitative variables.</p><p><strong>Results: </strong>We identified three distinct phenotypic clusters: Cluster A (n = 850, 33.1%), characterized by a predominance of women with low comorbidity burden; Cluster B (n = 830, 32.3%), mainly women with diabetes mellitus and high comorbidity; and Cluster C (n = 890, 34.5%), primarily men with a history of active smoking and respiratory comorbidities. Significant differences were observed in baseline characteristics and one-year mortality rates across the clusters: 18% for Cluster A, 33% for Cluster B, and 26.4% for Cluster C (P < 0.001). Cluster B had the shortest median time to death (90 days), followed by Clusters C (99 days) and A (144 days) (P < 0.001). Stratified Cox regression analysis identified age, cancer, respiratory failure, and laboratory parameters as predictors of mortality.</p><p><strong>Conclusion: </strong>Cluster analysis identified three distinct phenotypes within the HFp/mrEF population, highlighting significant heterogeneity in clinical profiles and prognostic implications. Women were classified into two distinct phenotypes: low-risk women and diabetic women with high mortality rates, while men had a more uniform profile with a higher prevalence of respiratory disease.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Educational attainment of children with congenital heart disease in the United Kingdom. 英国先天性心脏病患儿的受教育程度
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcad068
Daniel G W Cave, Zoë E Wands, Kirsten Cromie, Amy Hough, Kathryn Johnson, Mark Mon-Williams, James R Bentham, Richard G Feltbower, Adam W Glaser

Background: Educational attainment in children with congenital heart disease (CHD) within the UK has not been reported, despite the possibility of school absences and disease-specific factors creating educational barriers.

Methods and results: Children were prospectively recruited to the Born in Bradford birth cohort between March 2007 and December 2010. Diagnoses of CHD were identified through linkage to the congenital anomaly register and independently verified by clinicians. Multivariable regression accounted for relevant confounders. Our primary outcome was the odds of 'below expected' attainment in maths, reading, and writing at ages 4-11 years.Educational records of 139 children with non-genetic CHD were compared with 11 188 age-matched children with no major congenital anomaly. Children with CHD had significantly higher odds of 'below expected' attainment in maths at age 4-5 years [odds ratio (OR) 1.64, 95% confidence interval (CI) 1.07-2.52], age 6-7 (OR 2.03, 95% CI 1.32-3.12), and age 10-11 (OR 2.28, 95% CI 1.01-5.14). Odds worsened with age, with similar results for reading and writing. The odds of receiving special educational needs support reduced with age for children with CHD relative to controls [age 4-5: OR 4.84 (2.06-11.40); age 6-7: OR 3.65 (2.41-5.53); age 10-11: OR 2.73 (1.84-4.06)]. Attainment was similar for children with and without exposure to cardio-pulmonary bypass. Lower attainment was strongly associated with the number of pre-school hospital admissions.

Conclusion: Children with CHD have lower educational attainment compared with their peers. Deficits are evident from school entry and increase throughout primary school.

背景:英国先天性心脏病(CHD)患儿的受教育程度尚未报道,尽管可能存在缺课和疾病特定因素造成的教育障碍。方法:2007年3月至2010年12月,前瞻性地招募了出生在布拉德福德的儿童。冠心病的诊断是通过与先天性异常登记的联系来确定的,并由临床医生独立验证。多变量回归解释了相关混杂因素。我们的主要结果是4-11岁儿童在数学、阅读和写作方面的成绩“低于预期”的几率。结果:将139例非遗传性冠心病患儿的教育记录与1188例无重大先天性异常的年龄匹配患儿进行比较。在4-5岁、6-7岁(OR 2.03, 95% CI 1.32-3.12)和10-11岁(OR 2.28, 95% CI 1.01-5.14),患有冠心病的儿童数学成绩“低于预期”的几率明显更高。随着年龄的增长,这种可能性越来越大,阅读和写作的结果也差不多。与对照组相比,患有冠心病的儿童接受特殊教育需要支持的几率随着年龄的增长而降低(4-5岁:OR 4.84 (2.06-11.40);6-7岁:OR 3.65 (2.41-5.53);10-11岁:OR 2.73(1.84-4.06))。接受和未接受过心肺旁路治疗的儿童达到的效果相似。较低的学习成绩与学龄前儿童住院的数量密切相关。结论:冠心病患儿受教育程度低于同龄人。缺陷从入学开始就很明显,并且在整个小学阶段都在增加。
{"title":"Educational attainment of children with congenital heart disease in the United Kingdom.","authors":"Daniel G W Cave, Zoë E Wands, Kirsten Cromie, Amy Hough, Kathryn Johnson, Mark Mon-Williams, James R Bentham, Richard G Feltbower, Adam W Glaser","doi":"10.1093/ehjqcco/qcad068","DOIUrl":"10.1093/ehjqcco/qcad068","url":null,"abstract":"<p><strong>Background: </strong>Educational attainment in children with congenital heart disease (CHD) within the UK has not been reported, despite the possibility of school absences and disease-specific factors creating educational barriers.</p><p><strong>Methods and results: </strong>Children were prospectively recruited to the Born in Bradford birth cohort between March 2007 and December 2010. Diagnoses of CHD were identified through linkage to the congenital anomaly register and independently verified by clinicians. Multivariable regression accounted for relevant confounders. Our primary outcome was the odds of 'below expected' attainment in maths, reading, and writing at ages 4-11 years.Educational records of 139 children with non-genetic CHD were compared with 11 188 age-matched children with no major congenital anomaly. Children with CHD had significantly higher odds of 'below expected' attainment in maths at age 4-5 years [odds ratio (OR) 1.64, 95% confidence interval (CI) 1.07-2.52], age 6-7 (OR 2.03, 95% CI 1.32-3.12), and age 10-11 (OR 2.28, 95% CI 1.01-5.14). Odds worsened with age, with similar results for reading and writing. The odds of receiving special educational needs support reduced with age for children with CHD relative to controls [age 4-5: OR 4.84 (2.06-11.40); age 6-7: OR 3.65 (2.41-5.53); age 10-11: OR 2.73 (1.84-4.06)]. Attainment was similar for children with and without exposure to cardio-pulmonary bypass. Lower attainment was strongly associated with the number of pre-school hospital admissions.</p><p><strong>Conclusion: </strong>Children with CHD have lower educational attainment compared with their peers. Deficits are evident from school entry and increase throughout primary school.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138175954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The influence of socio-demographic and clinical factors on sick leave and return to work after open-heart surgery: a nationwide registry-based cohort study. 社会人口统计学和临床因素对心脏直视手术后病假和重返工作岗位的影响:一项基于全国注册的队列研究。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcad064
Michael Mortensen, Roy M Nilsen, Venny L Kvalheim, Johannes L Bjørnstad, Øyvind S Svendsen, Rune Haaverstad, Asgjerd L Moi

Aims: To estimate sick leave (SL) duration after first-time elective open-heart surgery and identify factors contributing to increased SL.

Methods and results: A retrospective nationwide cohort study combined data from the Norwegian Register for Cardiac Surgery and SL data from the Norwegian Labour and Welfare Administrations. All able-bodied adults who underwent first-time elective open-heart surgery in Norway between 2012 and 2021 were followed until 1 year after surgery. The impact of socio-demographic and clinical factors on SL after surgery was analysed using logistic regression and odds ratios. Of 5456 patients, 1643 (30.1%), 1798 (33.0%), 971 (17.8%), 1035 (18.9%), and 9 (0.2%) had SL of <3, 3-6, 6-9, and 9-12 months, and 1 year, respectively. SL >6 months was associated with female gender, primary education only, and average annual income. Post-operative stroke, post-operative renal failure, New York Heart Association Functional Classification system (NYHA) score >3, earlier myocardial infarction, and diabetes mellitus increased the odds of SL >6 months.

Conclusion: This study demonstrates that socio-demographic and clinical factors impact SL after first-time elective open-heart surgery. Patients who experience a stroke or develop renal failure after surgery have the highest odds of SL >6 months. Females and patients with low education levels, earlier myocardial infarction, or NYHA scores III-IV have a two-fold chance of SL >6 months. The findings allow for future investigations of pre- and post-surgery interventions that can most effectively reduce SL and aid return to work.

目的:估计首次选择性心脏直视手术后的病假(SL)持续时间,并确定导致SL增加的因素。方法和结果:一项全国性回顾性队列研究结合了挪威心脏外科注册中心的数据和挪威劳工和福利管理局的SL数据。2012年至2021年间,所有在挪威首次接受选择性心脏直视手术的健全成年人都接受了随访,直到手术后一年。采用逻辑回归和比值比分析了社会人口统计学和临床因素对术后SL的影响。在5456名患者中,1643名(30.1%)、1798名(33.0%)、971名(17.8%)、1035名(18.9%)和9名(0.2%)患有SL。6个月的SL与女性、仅小学教育和平均年收入有关。术后中风、术后肾功能衰竭、纽约心脏协会功能分类系统(NYHA)评分>3、早期心肌梗死和糖尿病增加了SL>6个月的几率。结论:本研究表明,社会人口统计学和临床因素会影响首次择期心脏直视手术后的SL。手术后经历中风或出现肾功能衰竭的患者SL>6个月的几率最高。女性和受教育程度低、早期心肌梗死或NYHA评分III-IV的患者发生SL>6个月的几率是女性和患者的两倍。这些发现为未来对术前和术后干预措施的调查提供了依据,这些干预措施可以最有效地减少SL并有助于重返工作岗位。
{"title":"The influence of socio-demographic and clinical factors on sick leave and return to work after open-heart surgery: a nationwide registry-based cohort study.","authors":"Michael Mortensen, Roy M Nilsen, Venny L Kvalheim, Johannes L Bjørnstad, Øyvind S Svendsen, Rune Haaverstad, Asgjerd L Moi","doi":"10.1093/ehjqcco/qcad064","DOIUrl":"10.1093/ehjqcco/qcad064","url":null,"abstract":"<p><strong>Aims: </strong>To estimate sick leave (SL) duration after first-time elective open-heart surgery and identify factors contributing to increased SL.</p><p><strong>Methods and results: </strong>A retrospective nationwide cohort study combined data from the Norwegian Register for Cardiac Surgery and SL data from the Norwegian Labour and Welfare Administrations. All able-bodied adults who underwent first-time elective open-heart surgery in Norway between 2012 and 2021 were followed until 1 year after surgery. The impact of socio-demographic and clinical factors on SL after surgery was analysed using logistic regression and odds ratios. Of 5456 patients, 1643 (30.1%), 1798 (33.0%), 971 (17.8%), 1035 (18.9%), and 9 (0.2%) had SL of <3, 3-6, 6-9, and 9-12 months, and 1 year, respectively. SL >6 months was associated with female gender, primary education only, and average annual income. Post-operative stroke, post-operative renal failure, New York Heart Association Functional Classification system (NYHA) score >3, earlier myocardial infarction, and diabetes mellitus increased the odds of SL >6 months.</p><p><strong>Conclusion: </strong>This study demonstrates that socio-demographic and clinical factors impact SL after first-time elective open-heart surgery. Patients who experience a stroke or develop renal failure after surgery have the highest odds of SL >6 months. Females and patients with low education levels, earlier myocardial infarction, or NYHA scores III-IV have a two-fold chance of SL >6 months. The findings allow for future investigations of pre- and post-surgery interventions that can most effectively reduce SL and aid return to work.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in atrial fibrillation-related mortality in Europe, 2008-2019. 2008-2019 年欧洲心房颤动相关死亡率趋势。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae007
Marco Zuin, Michele Malagù, Francesco Vitali, Cristina Balla, Martina De Raffele, Roberto Ferrari, Giuseppe Boriani, Matteo Bertini

Aims: Update data regarding the atrial fibrillation (AF)-related mortality trend in Europe remain scant. We assess the age- and sex-specific trends in AF-related mortality in the European states between the years 2008 and 2019.

Methods and results: Data on cause-specific deaths and population numbers by sex for European countries were retrieved through the publicly available World Health Organization mortality dataset for the years 2008-2019. Atrial fibrillation-related deaths were ascertained when the International Classification of Diseases, 10th Revision code I48 was listed as the underlying cause of death in the medical death certificate. To calculate annual trends, we assessed the average annual % change (AAPC) with relative 95% confidence intervals (CIs) using Joinpoint regression. During the study period, 773 750 AF-related deaths (202 552 males and 571 198 females) occurred in Europe. The age-adjusted mortality rate (AAMR) linearly increased from 12.3 (95% CI: 11.2-12.9) per 100 000 population in 2008 to 15.3 (95% CI: 14.7-15.7) per 100 000 population in 2019 [AAPC: +2.0% (95% CI: 1.6-3.5), P < 0.001] with a more pronounced increase among men [AAPC: +2.7% (95% CI: 1.9-3.5), P < 0.001] compared with women [AAPC: +1.7% (95% CI: 1.1-2.3), P < 0.001] (P for parallelism 0.01). Higher AAMR increases were observed in some Eastern European countries such as Latvia, Lithuania, and Poland, while the lower increases were mainly clustered in Central Europe.

Conclusion: Over the last decade, the age-adjusted AF-related mortality has increased in Europe, especially among males. Disparities still exist between Western and Eastern European countries.

目的:有关欧洲心房颤动相关死亡率趋势的最新数据仍然很少。我们评估了2008年至2019年间欧洲各国心房颤动相关死亡率的年龄和性别趋势:我们通过可公开获取的世界卫生组织(WHO)2008 年至 2019 年死亡率数据集,检索了欧洲各国按性别分列的特定死因和人口数量数据。心房颤动相关死亡在医学死亡证明中被列为基本死因的ICD-10代码I48时被确定。为了计算年度趋势,我们使用联结点回归法评估了平均(AAPC)年度百分比变化及相对 95% 置信区间 (CI)。在研究期间,欧洲共有 773 750 例心房颤动相关死亡(男性 202 552 例,女性 571 198 例)。年龄调整后死亡率(AAMR)从 2008 年的每 10 万人 12.3 例(95% CI:11.2 至 12.9 例)直线上升至 2019 年的每 10 万人 15.3 例(95% CI:14.7 至 15.7 例)[AAPC:+2.0%(95% CI:1.6 至 3.5),p 结论:在过去十年中,欧洲与年龄调整后心房颤动相关的死亡率有所上升,尤其是男性。西欧和东欧国家之间仍然存在差距。
{"title":"Trends in atrial fibrillation-related mortality in Europe, 2008-2019.","authors":"Marco Zuin, Michele Malagù, Francesco Vitali, Cristina Balla, Martina De Raffele, Roberto Ferrari, Giuseppe Boriani, Matteo Bertini","doi":"10.1093/ehjqcco/qcae007","DOIUrl":"10.1093/ehjqcco/qcae007","url":null,"abstract":"<p><strong>Aims: </strong>Update data regarding the atrial fibrillation (AF)-related mortality trend in Europe remain scant. We assess the age- and sex-specific trends in AF-related mortality in the European states between the years 2008 and 2019.</p><p><strong>Methods and results: </strong>Data on cause-specific deaths and population numbers by sex for European countries were retrieved through the publicly available World Health Organization mortality dataset for the years 2008-2019. Atrial fibrillation-related deaths were ascertained when the International Classification of Diseases, 10th Revision code I48 was listed as the underlying cause of death in the medical death certificate. To calculate annual trends, we assessed the average annual % change (AAPC) with relative 95% confidence intervals (CIs) using Joinpoint regression. During the study period, 773 750 AF-related deaths (202 552 males and 571 198 females) occurred in Europe. The age-adjusted mortality rate (AAMR) linearly increased from 12.3 (95% CI: 11.2-12.9) per 100 000 population in 2008 to 15.3 (95% CI: 14.7-15.7) per 100 000 population in 2019 [AAPC: +2.0% (95% CI: 1.6-3.5), P < 0.001] with a more pronounced increase among men [AAPC: +2.7% (95% CI: 1.9-3.5), P < 0.001] compared with women [AAPC: +1.7% (95% CI: 1.1-2.3), P < 0.001] (P for parallelism 0.01). Higher AAMR increases were observed in some Eastern European countries such as Latvia, Lithuania, and Poland, while the lower increases were mainly clustered in Central Europe.</p><p><strong>Conclusion: </strong>Over the last decade, the age-adjusted AF-related mortality has increased in Europe, especially among males. Disparities still exist between Western and Eastern European countries.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delineation of acute coronary syndromes: the acute total occlusion vs. ST-segment paradigm. 划分急性冠状动脉综合征:急性全闭塞与 ST 段范式。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae030
Kush P Patel, Andreas Baumbach
{"title":"Delineation of acute coronary syndromes: the acute total occlusion vs. ST-segment paradigm.","authors":"Kush P Patel, Andreas Baumbach","doi":"10.1093/ehjqcco/qcae030","DOIUrl":"10.1093/ehjqcco/qcae030","url":null,"abstract":"","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pre-hospital rule-out of non-ST-segment elevation acute coronary syndrome by a single troponin: final one-year outcomes of the ARTICA randomised trial. 通过单一肌钙蛋白排除非 ST 段抬高急性冠脉综合征的院前诊断:ARTICA 随机试验的最终一年结果。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae004
Goaris W A Aarts, Cyril Camaro, Eddy M M Adang, Laura Rodwell, Roger van Hout, Gijs Brok, Anouk Hoare, Frank de Pooter, Walter de Wit, Gilbert E Cramer, Roland R J van Kimmenade, Eva Ouwendijk, Martijn H Rutten, Erwin Zegers, Robert-Jan M van Geuns, Marc E R Gomes, Peter Damman, Niels van Royen

Background and aims: The healthcare burden of acute chest pain is enormous. In the randomized ARTICA trial, we showed that pre-hospital identification of low-risk patients and rule-out of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) with point-of-care (POC) troponin measurement reduces 30-day healthcare costs with low major adverse cardiac events (MACE) incidence. Here we present the final 1-year results of the ARTICA trial.

Methods: Low-risk patients with suspected NSTE-ACS were randomized to pre-hospital rule-out with POC troponin measurement or emergency department (ED) transfer. Primary 1-year outcome was healthcare costs. Secondary outcomes were safety, quality of life (QoL), and cost-effectiveness. Safety was defined as a 1-year MACE consisting of ACS, unplanned revascularization, or all-cause death. QoL was measured with EuroQol-5D-5L questionnaires. Cost-effectiveness was defined as 1-year healthcare costs difference per QoL difference.

Results: Follow-up was completed for all 863 patients. Healthcare costs were significantly lower in the pre-hospital strategy (€1932 ± €2784 vs. €2649 ± €2750), mean difference €717 [95% confidence interval (CI) €347 to €1087; P < 0.001]. In the total population, the 1-year MACE rate was comparable between groups [5.1% (22/434) in the pre-hospital strategy vs. 4.2% (18/429) in the ED strategy; P = 0.54]. In the ruled-out ACS population, 1-year MACE remained low [1.7% (7/419) vs. 1.4% (6/417)], risk difference 0.2% (95% CI -1.4% to 1.9%; P = 0.79). QoL showed no significant difference between strategies.

Conclusions: Pre-hospital rule-out of NSTE-ACS with POC troponin testing in low-risk patients is cost-effective, as expressed by a sustainable healthcare cost reduction and no significant effect on QoL. One-year MACE remained low for both strategies.

背景和目的:急性胸痛造成的医疗负担十分沉重。在随机进行的 ARTICA 试验中,我们发现院前识别低风险患者并通过床旁(POC)肌钙蛋白测量排除非 STE 段抬高型急性冠脉综合征(NSTE-ACS)可降低 30 天的医疗成本,同时降低重大心脏不良事件(MACE)的发生率。我们在此介绍 ARTICA 试验一年的最终结果:方法:疑似 NSTE-ACS 的低危患者被随机分配到使用 POC 肌钙蛋白测量进行院前排除或急诊科 (ED) 转院。一年的主要结果是医疗费用。次要结果为安全性、生活质量(QoL)和成本效益。安全性定义为一年的 MACE,包括 ACS、意外血运重建或全因死亡。QoL 采用 EuroQol-5D-5 L 问卷进行测量。成本效益定义为每QoL差异带来的一年医疗成本差异:结果:所有 863 名患者都完成了随访。院前策略的医疗费用明显较低(1932€±2784 欧元 vs 2649±2750欧元),平均差异为 717 欧元(95% 置信区间 [CI] 为 347 欧元至 1087 欧元;P通过 POC 肌钙蛋白检测对低危患者进行 NSTE-ACS 院前排除具有成本效益,可持续降低医疗成本,且对 QoL 无明显影响。两种方法的一年期MACE均较低。试验注册:Clinicaltrials.gov:NCT05466591,国际临床试验注册平台:NTR7346。
{"title":"Pre-hospital rule-out of non-ST-segment elevation acute coronary syndrome by a single troponin: final one-year outcomes of the ARTICA randomised trial.","authors":"Goaris W A Aarts, Cyril Camaro, Eddy M M Adang, Laura Rodwell, Roger van Hout, Gijs Brok, Anouk Hoare, Frank de Pooter, Walter de Wit, Gilbert E Cramer, Roland R J van Kimmenade, Eva Ouwendijk, Martijn H Rutten, Erwin Zegers, Robert-Jan M van Geuns, Marc E R Gomes, Peter Damman, Niels van Royen","doi":"10.1093/ehjqcco/qcae004","DOIUrl":"10.1093/ehjqcco/qcae004","url":null,"abstract":"<p><strong>Background and aims: </strong>The healthcare burden of acute chest pain is enormous. In the randomized ARTICA trial, we showed that pre-hospital identification of low-risk patients and rule-out of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) with point-of-care (POC) troponin measurement reduces 30-day healthcare costs with low major adverse cardiac events (MACE) incidence. Here we present the final 1-year results of the ARTICA trial.</p><p><strong>Methods: </strong>Low-risk patients with suspected NSTE-ACS were randomized to pre-hospital rule-out with POC troponin measurement or emergency department (ED) transfer. Primary 1-year outcome was healthcare costs. Secondary outcomes were safety, quality of life (QoL), and cost-effectiveness. Safety was defined as a 1-year MACE consisting of ACS, unplanned revascularization, or all-cause death. QoL was measured with EuroQol-5D-5L questionnaires. Cost-effectiveness was defined as 1-year healthcare costs difference per QoL difference.</p><p><strong>Results: </strong>Follow-up was completed for all 863 patients. Healthcare costs were significantly lower in the pre-hospital strategy (€1932 ± €2784 vs. €2649 ± €2750), mean difference €717 [95% confidence interval (CI) €347 to €1087; P < 0.001]. In the total population, the 1-year MACE rate was comparable between groups [5.1% (22/434) in the pre-hospital strategy vs. 4.2% (18/429) in the ED strategy; P = 0.54]. In the ruled-out ACS population, 1-year MACE remained low [1.7% (7/419) vs. 1.4% (6/417)], risk difference 0.2% (95% CI -1.4% to 1.9%; P = 0.79). QoL showed no significant difference between strategies.</p><p><strong>Conclusions: </strong>Pre-hospital rule-out of NSTE-ACS with POC troponin testing in low-risk patients is cost-effective, as expressed by a sustainable healthcare cost reduction and no significant effect on QoL. One-year MACE remained low for both strategies.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time Waits for No One: Expediting and Expanding Access to Transcatheter Aortic Valve Implantation. 时不我待:加快和扩大经导管主动脉瓣植入术的普及。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-08 DOI: 10.1093/ehjqcco/qcae070
Andrew M Goldsweig, Ashequl Islam
{"title":"Time Waits for No One: Expediting and Expanding Access to Transcatheter Aortic Valve Implantation.","authors":"Andrew M Goldsweig, Ashequl Islam","doi":"10.1093/ehjqcco/qcae070","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae070","url":null,"abstract":"","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Heart Journal - Quality of Care and Clinical Outcomes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1